Nef protein induces differential effects in CD8+ cells from HIV-1-infected patients

European Journal of Clinical Investigation

Volumn 29, Issue 11, 1999, Pages 980-991

  Silvestris, Franco ^a   Camarda, G ^b   Prete, A Del ^b   Tucci, M ^b   Dammacco, F ^b  

^a UNIVERSITY OF BARI   (Italy)

^b NONE

Author keywords

CD8+ cells; Cytolysis; Fas L; HIV; Nef

Indexed keywords

CD57 ANTIGEN; CD8 ANTIGEN; DNA; FAS LIGAND; HLA DR ANTIGEN; KI 67 ANTIGEN; MESSENGER RNA; NEF PROTEIN;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA CONTENT; DNA TRANSFECTION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL;

3T3 CELLS; ANIMALS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COCULTURE TECHNIQUES; GENE PRODUCTS, NEF; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MICE; RECOMBINANT PROTEINS; REFERENCE VALUES; TRANSFECTION;

EID: 0032738670     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1999.00562.x     Document Type: Article

References (59)

1. 1 Subbramanian RA, Cohen EA. Molecular biology of the human immunodeficiency virus accessory protein, J Virol 1994; 68: 6831-5.
2. 2 Cullen BR. Regulation of HIV gene expression. AIDS 1995; 9 (Suppl, A): 19-32.
3. 3 Trono D. HIV accessory proteins: leading roles for the supporting cast. Cell 1995; 82: 1898-923.
4. 4 Allan JS, Coligan JE, Lee TH et al. A new HTLV-III/LAV encoded antigen detected by antibodies from AIDS patients. Science 1985; 20: 810-3.
5. 5 Curtain CC, Lowe MG, Arunagiri CK, Mobley PW, MacReadie IG, Azad AA. Cytotoxix activity of the amino-terminal region of HIV type I Nef protein. AIDS Res Hum Retroviruses 1997; 13: 1213-20.
6. 6 Franchini G, Robert-Guroff M, Ghrayeb J, Chang NT, Wong-Staal F. Cytoplasmic localization of the HTLV-III 3′ orf protein in cultured T cells. Virology 1986; 155: 593-9.
7. 7 Guy B, Rivière Y, Dott K, Regnault A, Kieny MP. Mutational analysis of the HIV Nef protein. Virology 1990; 176: 413-25.
8. 8 Kienzle N, Bachmann M, Muller WEG, Muller-Lantzsch N. Expression and cellular localization of the Nef protein from human immunodeficiency virus-1 in stably transfected B-cells. Arch Virol 1992; 124: 123-32.
9. 9 Ahmad N, Venkatesan S. Nef protein of HIV-1 is a transcriptional represser of HTV-1 LTR. Science 1988; 241: 1481-85.
10. 10 Luciw PA, Cheng-Mayer C, Levy JA. Mutational analysis of the human immunodeficiency virus: the orf-B region down-modulates virus replication. Proc Natl Acad Sci USA 1897; 84: 1434-8.
11. 11 Niederman TMJ, Thielan BJ, Ratner L. Human immunodeficiency virus type 1 negative factor is a transcriptional silencer. Proc Natl Acad Sci USA 1989; 86: 1128-32.
12. 12 Terwilliger E, Sodroski JG, Rosen CA, Haseltine WA. Effects of mutations within the 3′ orf open reading frame of human T-cell lymphotropic virus type HT (HTLV-III/LAV) on replication and cytopathogenicity. J Virol 1986; 60: 754-60.
13. 13 Kestler HW, Ringler DJ, Mori K et al. Importance of the Nef gene for maintenance of high virus loads and development of AIDS. Cell 1991,65: 651-62.
14. 14 Jamieson BD, Aldrovandi GM3 Planelles V et al. Requirement of human immunodeficiency virus type I nef for in vivo replication and pathogenicity. J Virol 1994; 68: 3478-85.
15. 15 Deacon NJ, Tsykin A, Solomon A et al. Genomic structure of an attenuated quasi-species of HIV-1 from a blood transfusion donor and recipients. Science 1995; 270: 988-91.
16. 16 Greenway A, Azad A, McPhee D. Human immunodeficiency virus type 1 Nef protein inhibits activation pathways in peripheral blood mononuclear cells and T-cell lines. J Virol 1995,69: 1842-50.
17. 17 Luria S, Chambers I, Berg P. Expression of the type 1 human immunodeficiency virus Nef protein in T cells prevents antigen receptor-mediated induction of interleukin-2 mRNA. Proc Natl Acad Sci USA 1991; 88: 5326-30.
18. 18 Bandres JC, Ratner L. Human immunodeficiency virus type 1 Nef protein down-regulates transcription factors NFkB and AP-1 in human T cells in vitro after T-cell receptor stimulation. J Virol 1994; 68: 3243-9.
19. 19 Collette Y, Chang HL, Cerdan C et al. Specific Th1 cytokine down-regulation associated with primary clinically derived human immunodeficiency virus type 1 nef gene-induced expression. J Immunol 1996; 156: 360-70.
20. + T cells. FEBS Lett 1996; 393: 105-8.
21. + T cells. FEBS Lett 1996; 393: 93-6.
22. 22 Banda NK, Bernier J, Kurahara DK et al. Cross-linking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med 1992; 176: 1099-10:6.
23. 23 Westendorp MO, Frank R, Ochsembauer C et al. Sensitization of T cell to CD95-mediated apoptosis by HIV-1 tat and gp120. Nature 1995; 375: 497-500.
24. + cells. J Immunol 1994; 153: 5826-37.
25. 25 Hua J, Blai W, Truant R, Cullen BR. Identification of regions in HIV-1 Nef required for efficient down regulation of cell surface CD4. Virology 1997; 231: 231-8.
26. 26 Okada H, Takei R, Tashiro M. Hiv-1 nef protein induced apoptotic cytolysis of a broad spectrum of infected human blood cells independently of CD95 (Fas). FEBS Lett 1997; 414: 603-6.
27. 27 Okada H, Takei R, Tashiro M. Nef protein induces apoptotic cytolysis of murine lymphoid cells independently of CD95 (Fas) and its suppression by serine/threonine protein kinase inhibitors. FEBS Lett 1997; 417: 61-4.
28. 28 Torres BA, Johnson HM. Identification of an HIV-1 Nef peptide that binds to HLA class II antigens. Biochem Biophys Res Comm 1994; 200: 1059-65.
29. 29 Torres BA, Tanabe T, Yamamoto JK, Johnson MH. HTV encodes for its own CD4 T cell superantigen. Biochem Biophys Res Comm 1996; 225: 672-8.
30. 30 Poggi A, Panzeri MC, Moretta L, Zocchi MR. CD31-triggered rearrangement of the actin cytoskeleton in human natural killer cells. Eur J Immunol 1996; 26; 817-24.
31. 31 Silvestris F, Cafforio P, Frassanito MA et a.l Overexpression of Fas antigen on T cells in advanced HIV-infection: differential ligation constantly induces apoptosis. AIDS 1996; 10: 131-41.
32. 32 Silvestris F, Nagata S, Cafforio P, Silvestris N, Dammacco F. Cross-linking of Fas by antibodies to a peculiar domain of gp120x V3 loop can enhance T cell apoptosis in HIV-1-infected patients. J Exp Med 1996; 184: 2287-300.
33. + T cells. Immunol Today 1996; 17: 217-24.
34. 34 De Ronde A, Klaver B, Keulen W, Smit L, Goudsmit J. Natural HIV-1 Nef accelerates virus replication in primary human lymphocytes. Virology 1992; 188: 391-5.
35. 35 Spina CA, Kwoh TJ, Chowers MY, Guatelli JC, Richman DD. The importance of nef in the induction of human immunodeficiency virus type I replication from primary quiescent CD4 lymphocytes. J Exp Med 1994; 179: 115-22.
36. 36 Fujinaga K, Zhong Q, Nakaya T et al. Extracellular Nef protein regulates productive HIV-1 infection from latency. J Immunol 1995; 155: 5289-98.
37. 37 Cullen BR. The role of Nef in the replication cycles of the human and simian immunodeficiency viruses. Virology 1994; 205: 1-6.
38. + T lymphocytes and for the blocking of the Nef function by anti-Nef antibodies. Vaccine 1993; 11: 837-42.
39. 39 Curtain CC, Separovic F, Rivett D et al. Fusogenic activity of amino-terminal region of HIV type 1 Nef protein. AIDS Res Hum Retrovirus 1994; 10: 1231-40.
40. 40 Hope MJ, Bally MB, Webb G, Cullis PR. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of site distribution, trapped, & ability to maintain a membrane potential. Biochem Biophys Acta 1985; 812: 55-6.
41. 41 Page KA, Van Schooten WCA, Feinberg MB. Human immunodeficiency virus type 1 Nef does not alter T cell sensitivity to antigen-specific stimulation. J Virol 1997; 71: 3776-87.
42. 42 Lanier LL, Loken MR. Human lymphocyte subpopulations identified using three colour immunofluorescence and flow cytometric analysis: correlation of Leu-2, Leu-7, Leu-8 and Leu-11. J Immunol 1984; 132: 151-60.
43. + cells that suppress B cell differentiation. J Immunol 1984; 133: 2461-9.
44. 44 Joly P, Guillon JM, Mayaud C et al. Cell-mediated suppression of HIV-specific cytotoxic T lymphocytes. J Immunol 1989; 143: 2193-201.
45. + T lymphocytes in normal, healthy individuals are oligoclonal and respond to human cytomegalovirus. J Immunol 1995; 155: 5046-56.
46. 46 James SP, Neckers LM, Graeff AS, Cossman J, Balch CM, Strber W. Suppression of immunoglobulin synthesis by lymphocyte populations in patients with Crohn's disease. Gastroenterology 1984; 66: 1510-5.
47. 47 Baumert E, Wolff VG, Schlesier M, Peter HH. Immunophenotypical alterations in a subset of patients with common variable immunodeficiency. Clin Exp Immunol 1992; 90: 25-31.
48. 48 Toso JF, Chen CH, Mohr JR et al. Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication. J Infect Dis 1995; 17: 964-73.
49. + suppressor lymphocytes in the blood of long-term surviving patients after bone marrow transplantation. J Immunol 1986; 137: 2180-6.
50. + T lymphocytes from patients suffering from AIDS and immunosuppressed bone marrow recipients. Eur J Immunol 1994; 24: 2882-8.
51. + lymphocytes from AIDS patients inhibits T cell cytotoxicity. Eur J Immunol 1991; 21: 737-41.
52. 52 Silvestris F, Camarda G, Cafforio P, Dammacco F. Upregulation of Fas-ligand secretion in non-lymphopenic stages of HIV-1 infection. AIDS 1998; 12: 1103-4.
53. 53 Sieg S, Smoth DI, Yildirim Z, Kaplan D. Fas ligand deficiency in HTV disease, Prac Natl Acad Sci USA 1997; 94: 5860-5.
54. + T lymphocytes from HIV-infected individuals is mediated by Fas-L and tumor necrosis factor. J Exp Med 1997; 185: 55-64.
55. 55 Brinchmann JE, Rosok BI, Spurkland A. Activation and proliferation of CD8+ T cells in lymphoid tissues of HIV-1-infected individuals in the absence of the high-affinity IL-2 receptor. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 332-8.
56. 56 Orendi JM, Bloem AC, Borleffs JC et al. Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. J Infect Dis 1998; 178: 1279-87.
57. 57 Giorgi JV, Majchrowicz MA, Johnson TD, Hultin P, Matud J, Delets R. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS, 1998; 12: 1833-44.
58. + cell anti-HIV activity: non lytic suppression of virus replication. AIDS Res Hum Retrovirus 1992; 8: 1039-50.
59. 59 Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. Hiv-1 Nef protein protects infected primary cells against killing by cytotoxic lymphocytes. Nature 1998; 391: 397-401.